2021
Prevalence of Dyslipidemia and Availability of Lipid-Lowering Medications Among Primary Health Care Settings in China
Lu Y, Zhang H, Lu J, Ding Q, Li X, Wang X, Sun D, Tan L, Mu L, Liu J, Feng F, Yang H, Zhao H, Schulz WL, Krumholz HM, Pan X, Li J, Huang C, Dong Z, Jiang B, Guo Z, Zhang Y, Sun J, Liu Y, Ren Z, Meng Y, Wang Z, Xi Y, Xing L, Tian Y, Liu J, Fu Y, Liu T, Sun W, Yan S, Jin L, Zheng Y, Wang J, Yan J, Xu X, Chen Y, Xing X, Zhang L, Zhong W, Fang X, Zhu L, Xu Y, Guo X, Xu C, Zhou G, Fan L, Qi M, Zhu S, Qi J, Li J, Yin L, Liu Q, Geng Q, Feng Y, Wang J, Wen H, Han X, Liu P, Ding X, Xu J, Deng Y, He J, Liu G, Jiang C, Zha S, Yang C, Bai G, Yu Y, Tashi Z, Qiu L, Hu Z, He H, Zhang J, Zhou M, Li X, Zhao J, Ma S, Ma Y, Huang Y, Zhang Y, Li F, Shen J. Prevalence of Dyslipidemia and Availability of Lipid-Lowering Medications Among Primary Health Care Settings in China. JAMA Network Open 2021, 4: e2127573. PMID: 34586366, PMCID: PMC8482054, DOI: 10.1001/jamanetworkopen.2021.27573.Peer-Reviewed Original ResearchConceptsAtherosclerotic cardiovascular diseaseLipid-lowering medicationsPrimary care institutionsPrevalence of dyslipidemiaControl of dyslipidemiaLipoprotein cholesterolCare institutionsControl rateFemale sexCardiovascular diseaseMAIN OUTCOMEHigh riskNonstatin lipid-lowering drugsHigh-density lipoprotein cholesterolLow-density lipoprotein cholesterolPrimary health care settingsMajor public health problemLipid lowering medicationsMillion Persons ProjectOverall control rateLDL-C levelsLipid-lowering drugsCross-sectional studyPublic health problemHealth care settings
2019
Whole Genome Sequencing to Characterize Monogenic and Polygenic Contributions in Patients Hospitalized with Early-Onset Myocardial Infarction
Khera AV, Chaffin M, Zekavat S, Collins RL, Roselli C, Natarajan P, Lichtman JH, D'Onofrio G, Mattera J, Dreyer R, Spertus JA, Taylor KD, Psaty BM, Rich SS, Post W, Gupta N, Gabriel S, Lander E, Ida Chen Y, Talkowski ME, Rotter JI, Krumholz HM, Kathiresan S. Whole Genome Sequencing to Characterize Monogenic and Polygenic Contributions in Patients Hospitalized with Early-Onset Myocardial Infarction. Circulation 2019, 139: 1593-1602. PMID: 30586733, PMCID: PMC6433484, DOI: 10.1161/circulationaha.118.035658.Peer-Reviewed Original Research
2017
Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers: Insights Derived From the FOURIER Trial
Arrieta A, Hong JC, Khera R, Virani SS, Krumholz HM, Nasir K. Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers: Insights Derived From the FOURIER Trial. JAMA Cardiology 2017, 2: 1369-1374. PMID: 29049467, PMCID: PMC5814995, DOI: 10.1001/jamacardio.2017.3655.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnticholesteremic AgentsCardiovascular DiseasesCholesterol, LDLCost-Benefit AnalysisDecision Support TechniquesDrug Therapy, CombinationFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypercholesterolemiaInsuranceInsurance, HealthInsurance, Health, ReimbursementMaleMarkov ChainsMiddle AgedMyocardial InfarctionPCSK9 InhibitorsQuality-Adjusted Life YearsStrokeUnited StatesConceptsQuality-adjusted life yearsIncremental cost-effectiveness ratioCost-effectiveness ratioProprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitorsCurrent pricesLife yearsPrivate payersAdditional quality-adjusted life yearPreliminary cost-effectiveness analysisCost-effectiveness standardsProbabilistic sensitivity analysesCost-effectiveness analysisPrivate payer perspectiveCost-effectiveness assessmentNegative returnsHealth system perspectiveSignificant discountUS dollarsDrug pricesPatent protectionPricesStatin treatment strategiesHealth insuranceTime horizonSubtilisin/kexin type 9 inhibitorsTreatment of Cholesterol in 2017
Krumholz HM. Treatment of Cholesterol in 2017. JAMA 2017, 318: 417-418. PMID: 28738130, DOI: 10.1001/jama.2017.6753.Peer-Reviewed Original Research
2016
Sex differences in lipid profiles and treatment utilization among young adults with acute myocardial infarction: Results from the VIRGO study
Lu Y, Zhou S, Dreyer RP, Caulfield M, Spatz ES, Geda M, Lorenze NP, Herbert P, D'Onofrio G, Jackson EA, Lichtman JH, Bueno H, Spertus JA, Krumholz HM. Sex differences in lipid profiles and treatment utilization among young adults with acute myocardial infarction: Results from the VIRGO study. American Heart Journal 2016, 183: 74-84. PMID: 27979045, PMCID: PMC5459396, DOI: 10.1016/j.ahj.2016.09.012.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionLipid profileYoung womenLipoprotein cholesterolLipoprotein profileMyocardial infarctionTreatment utilizationLow-density lipoprotein cholesterolHigh-density lipoprotein cholesterolLow HDL cholesterol levelsYoung adultsHigh-intensity doseMajor lipid abnormalitiesSex differencesAdverse lipid profileFavorable lipoprotein profileHDL cholesterol ratioLower total cholesterolHDL cholesterol levelsHigher HDL cholesterolImportant risk factorHigher mortality riskMultivariate regression analysisVIRGO StudyCardiovascular outcomes
2014
The Guidelines Battle on Starting Statins
D'Agostino RB, Ansell BJ, Mora S, Krumholz HM. The Guidelines Battle on Starting Statins. New England Journal Of Medicine 2014, 370: 1652-1658. PMID: 24758622, DOI: 10.1056/nejmclde1314766.Peer-Reviewed Original Research
2013
Target cardiovascular risk rather than cholesterol concentration
Krumholz HM. Target cardiovascular risk rather than cholesterol concentration. The BMJ 2013, 347: f7110. PMID: 24284344, DOI: 10.1136/bmj.f7110.Peer-Reviewed Original Research
2012
2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons
Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, Douglas PS, Foody JM, Gerber TC, Hinderliter AL, King SB, Kligfield PD, Krumholz HM, Kwong RY, Lim MJ, Linderbaum JA, Mack MJ, Munger MA, Prager RL, Sabik JF, Shaw LJ, Sikkema JD, Smith CR, Smith SC, Spertus JA, Williams SV. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Journal Of The American College Of Cardiology 2012, 60: e44-e164. PMID: 23182125, DOI: 10.1016/j.jacc.2012.07.013.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAdrenergic beta-AntagonistsAlcohol DrinkingAngina PectorisBody WeightCholesterol, LDLClopidogrelComorbidityCost of IllnessDepressionDiabetes ComplicationsDisease ManagementElectrocardiographyExerciseExercise TestGlycated HemoglobinHealth BehaviorHumansHypertensionLife StyleMyocardial InfarctionMyocardial IschemiaMyocardial RevascularizationPhysical ExaminationPlatelet Aggregation InhibitorsPractice Guidelines as TopicQuality of LifeRisk AssessmentRisk FactorsRisk Reduction BehaviorSmoking CessationTiclopidineConceptsAmerican CollegeAmerican Heart Association Task ForcePreventive Cardiovascular Nurses AssociationCardiology Foundation/American Heart Association Task ForceManagement of patientsThoracic surgeryPractice guidelinesCardiovascular AngiographyThoracic surgeonsSTS guidelinesA ReportNurses AssociationAmerican AssociationTask ForceAssociationGuidelinesPatientsSurgeryAngiographyPhysiciansDiagnosisSurgeons
2011
Statin Use in Outpatients With Obstructive Coronary Artery Disease
Arnold SV, Spertus JA, Tang F, Krumholz HM, Borden WB, Farmer SA, Ting HH, Chan PS. Statin Use in Outpatients With Obstructive Coronary Artery Disease. Circulation 2011, 124: 2405-2410. PMID: 22064595, PMCID: PMC3527107, DOI: 10.1161/circulationaha.111.038265.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overArterial Occlusive DiseasesCardiovascular DiseasesCholesterol, LDLCoronary Artery DiseaseFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleMiddle AgedOutpatientsPractice Guidelines as TopicProspective StudiesRegistriesRetrospective StudiesRisk FactorsTreatment OutcomeConceptsObstructive coronary artery diseaseLow-density lipoprotein cholesterol levelsCoronary artery diseaseLipoprotein cholesterol levelsLipid-lowering therapyCholesterol levelsStatin therapyUntreated patientsStatin treatmentArtery diseaseLow-density lipoprotein cholesterol valuesNonstatin lipid-lowering medicationsRobust clinical trial evidenceRecent coronary revascularizationClinical trial evidenceLipid-lowering medicationsRoutine outpatient careLipoprotein cholesterol valuesRate of treatmentNonstatin medicationsNonstatin therapiesOutpatient registryCardiovascular morbidityCoronary revascularizationLipid management
2010
Shifting views on lipid lowering therapy
Krumholz HM, Hayward RA. Shifting views on lipid lowering therapy. The BMJ 2010, 341: c3531. PMID: 20667950, DOI: 10.1136/bmj.c3531.Peer-Reviewed Original ResearchOptimizing statin treatment for primary prevention of coronary artery disease.
Hayward RA, Krumholz HM, Zulman DM, Timbie JW, Vijan S. Optimizing statin treatment for primary prevention of coronary artery disease. Annals Of Internal Medicine 2010, 152: 69-77. PMID: 20083825, DOI: 10.7326/0003-4819-152-2-201001190-00004.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedCholesterol, LDLClinical Trials as TopicComputer SimulationCoronary Artery DiseaseDrug Administration ScheduleFemaleGuideline AdherenceHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleMiddle AgedPrimary PreventionQuality-Adjusted Life YearsRisk FactorsSensitivity and SpecificityTreatment OutcomeConceptsHigh-dose statinsQuality Enhancement Research InitiativeStatin therapyMore QALYsNational Cholesterol Education Program III guidelinesTreatment approachesCoronary artery disease preventionVeterans Affairs Health Services ResearchDoses of statinsCoronary artery diseaseRisk factor dataAvailable clinical dataYears of treatmentTarget approachBase-case analysisHealth services researchPersons 75 yearsStatin doseStatin trialsCAD eventsStatin treatmentArtery diseaseCAD riskPrimary preventionMyocardial infarction
2008
Use of Ezetimibe in the United States and Canada
Jackevicius CA, Tu JV, Ross JS, Ko DT, Krumholz HM. Use of Ezetimibe in the United States and Canada. New England Journal Of Medicine 2008, 358: 1819-1828. PMID: 18375999, DOI: 10.1056/nejmsa0801461.Peer-Reviewed Original ResearchConceptsLipid-lowering agentsLow-density lipoprotein cholesterolLipid-lowering guidelinesRatio of prescriptionsUse of ezetimibeTreatment of hyperlipidemiaStatin useCohort studyLipoprotein cholesterolSecondary preventionStatin prescriptionClinical outcomesPrescribing practicesEzetimibeIMS HealthUnited StatesPrescriptionMonthly numberFirst optionDistinct patterns
2006
Hydroxymethylglutaryl‐CoA Reductase Inhibitors in Older Persons with Acute Myocardial Infarction: Evidence for an Age–Statin Interaction
Foody JM, Rathore SS, Galusha D, Masoudi FA, Havranek EP, Radford MJ, Krumholz HM. Hydroxymethylglutaryl‐CoA Reductase Inhibitors in Older Persons with Acute Myocardial Infarction: Evidence for an Age–Statin Interaction. Journal Of The American Geriatrics Society 2006, 54: 421-430. PMID: 16551308, PMCID: PMC2797316, DOI: 10.1111/j.1532-5415.2005.00635.x.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAged, 80 and overAtorvastatinCholesterol, LDLDrug PrescriptionsFatty Acids, MonounsaturatedFemaleFluvastatinFollow-Up StudiesHeptanoic AcidsHumansHydroxymethylglutaryl-CoA Reductase InhibitorsIndolesLovastatinMaleMyocardial InfarctionOdds RatioPravastatinPyridinesPyrrolesRetrospective StudiesSurvival RateTreatment OutcomeConceptsAcute myocardial infarctionHydroxymethylglutaryl-CoA reductase inhibitorsStatin therapyMyocardial infarctionLower mortalityOlder personsReductase inhibitorsPrincipal discharge diagnosisAcute care hospitalsCause mortalityEligible patientsOlder patientsYounger patientsCare hospitalDischarge prescriptionsPrimary outcomeDischarge diagnosisHospital characteristicsEfficacy dataMedicare patientsMultivariable modelObservational studyPatientsStatinsDischarge statins
2004
Clinical trial of an educational intervention to achieve recommended cholesterol levels in patients with coronary artery disease
Lichtman JH, Amatruda J, Yaari S, Cheng S, Smith GL, Mattera JA, Roumanis SA, Wang Y, Radford MJ, Krumholz HM. Clinical trial of an educational intervention to achieve recommended cholesterol levels in patients with coronary artery disease. American Heart Journal 2004, 147: 522-528. PMID: 14999204, DOI: 10.1016/j.ahj.2003.06.003.Peer-Reviewed Original ResearchConceptsLDL cholesterol target levelsCholesterol target levelsProportion of patientsCoronary artery diseaseUsual care groupArtery diseaseLevels 1 yearCholesterol managementCare groupEducational interventionPatient knowledgeLow-density lipoprotein cholesterol (LDL-C) target levelsTarget levelCholesterol knowledgeUsual careClinical characteristicsSecondary outcomesPrimary outcomeCholesterol levelsClinical trialsIntervention groupPatientsHospitalizationDiseaseIntervention
1998
Primary Prevention of Coronary Heart Disease: Guidance From Framingham
Grundy S, Balady G, Criqui M, Fletcher G, Greenland P, Hiratzka L, Houston-Miller N, Kris-Etherton P, Krumholz H, LaRosa J, Ockene I, Pearson T, Reed J, Washington R, Smith S. Primary Prevention of Coronary Heart Disease: Guidance From Framingham. Circulation 1998, 97: 1876-1887. PMID: 9603549, DOI: 10.1161/01.cir.97.18.1876.Peer-Reviewed Original Research